Page 41 - Read Online

D'Souza et al. J Cancer Metastasis Treat 2022;8:28 https://dx.doi.org/10.20517/2394-4722.2022.51 Page 13 of 15

34. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling
domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010;18:413-20. DOI
PubMed PMC
35. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody
K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-6. PubMed
36. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74:2907-12. DOI
PubMed PMC
37. Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016;6:133-46.
DOI PubMed PMC
38. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6. DOI
39. Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res
2021;9:11. DOI
40. Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther 2021;21:473-
86. DOI PubMed
41. Klampatsa A, Achkova DY, Davies DM, et al. Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-
targeted CAR T-cells. Cancer Lett 2017;393:52-9. DOI PubMed
42. Al-Taei S, Salimu J, Lester JF, et al. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural
mesothelioma. Lung Cancer 2012;77:312-8. DOI PubMed
43. Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma
(MPM). Cancers (Basel) 2017;9:115. DOI PubMed PMC
44. Thayaparan T, Petrovic RM, Achkova DY, et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Oncoimmunology 2017;6:e1363137. DOI PubMed PMC
45. Hyrenius-Wittsten A, Su Y, Park M, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor
activity in mouse models. Sci Transl Med 2021;13:eabd8836. DOI PubMed PMC
46. Bughda R, Dimou P, D’Souza RR, Klampatsa A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on
tumor stroma. Immunotargets Ther 2021;10:313-23. DOI PubMed PMC
47. Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive
malignant pleural mesothelioma (FAPME-1). BMC Cancer 2012;12:615. DOI PubMed PMC
48. Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific
re-directed T cells. J Transl Med 2013;11:187. DOI PubMed PMC
49. Hiltbrunner S, Britschgi C, Schuberth P, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients
with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol 2021;32:120-1. DOI PubMed
50. Blum Y, Meiller C, Quetel L, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for
clinical applications. Nat Commun 2019;10:1333. DOI PubMed PMC
51. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.
Cancer Sci 2012;103:868-74. DOI PubMed PMC
52. Kiyotani K, Park JH, Inoue H, et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural
mesothelioma. Oncoimmunology 2017;6:e1278330. DOI PubMed PMC
53. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54.
DOI PubMed
54. Oehl K, Vrugt B, Opitz I, Meerang M. Heterogeneity in malignant pleural mesothelioma. Int J Mol Sci 2018;19:1603. DOI PubMed
PMC
55. Lee HS, Jang HJ, Choi JM, et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight
2018;3:98575. DOI PubMed PMC
56. Chen R, Lee WC, Fujimoto J, et al. Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma
under dasatinib treatment. Clin Cancer Res 2020;26:5477-86. DOI PubMed PMC
57. Sneddon S, Rive CM, Ma S, et al. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.
Oncoimmunology 2020;9:1684713. DOI PubMed PMC
58. Mansfield AS, Peikert T, Smadbeck JB, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J
Thorac Oncol 2019;14:276-87. DOI PubMed PMC
59. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov 2018;8:1219-26. DOI PubMed
60. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin
Oncol 2020;17:147-67. DOI PubMed PMC
61. Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in immune cell content in malignant pleural mesothelioma. Int
J Mol Sci 2018;19:1041. DOI PubMed PMC
62. Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med 2017;68:139-52. DOI PubMed
63. Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol 2019;12:62. DOI PubMed PMC
64. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC
complexes. Nature 1995;375:148-51. DOI PubMed